📊 STXS Key Takeaways
Is Stereotaxis, Inc. (STXS) a Good Investment?
Stereotaxis shows explosive revenue growth (+6833% YoY) with healthy 52.7% gross margins, but this masks severe operational challenges. The company operates at a -68.3% operating margin while burning $13.7M in annual operating cash flow against only $13.4M in cash reserves, creating an unsustainable 1-year cash runway without profitability achievement or capital infusion.
Why Buy Stereotaxis, Inc. Stock? STXS Key Strengths
- Exceptional revenue growth of 6833% YoY indicates significant commercial traction in medical device market
- Strong gross margin of 52.7% demonstrates viable unit economics and pricing power
- Minimal debt burden (0.02x debt-to-equity) and adequate near-term liquidity (1.51x current ratio) reduce financial distress risk
STXS Stock Risks: Stereotaxis, Inc. Investment Risks
- Negative operating cash flow of -$13.7M annually with only $13.4M cash reserves creates critical 12-month survival runway
- Operating losses of $22.1M on $32.4M revenue (-68.3% margin) indicate severe inability to convert gross profit to operating profit
- Massive negative profitability metrics (ROE -160.5%, ROA -41.4%, net margin -66.8%) show capital is being destroyed, not deployed productively
Key Metrics to Watch
- Path to operating profitability and timeline to positive operating cash flow
- Cash burn rate and runway duration given current operating losses
- Revenue sustainability and customer concentration risk given 6833% YoY growth
Stereotaxis, Inc. (STXS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Stereotaxis, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
STXS Profit Margin, ROE & Profitability Analysis
STXS vs Healthcare Sector: How Stereotaxis, Inc. Compares
How Stereotaxis, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Stereotaxis, Inc. Stock Overvalued? STXS Valuation Analysis 2026
Based on fundamental analysis, Stereotaxis, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Stereotaxis, Inc. Balance Sheet: STXS Debt, Cash & Liquidity
STXS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Stereotaxis, Inc.'s revenue has remained relatively flat over the 5-year period, with a 8% decline. The most recent EPS of $-0.30 indicates the company is currently unprofitable.
STXS Revenue Growth, EPS Growth & YoY Performance
STXS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $7.5M | -$6.2M | $-0.07 |
| Q2 2025 | $4.5M | -$3.8M | $-0.05 |
| Q1 2025 | $6.9M | -$4.5M | $-0.06 |
| Q3 2024 | $7.8M | -$5.4M | $-0.07 |
| Q2 2024 | $4.5M | -$5.0M | $-0.07 |
| Q1 2024 | $6.5M | -$4.5M | $-0.06 |
| Q3 2023 | $7.7M | -$4.9M | $-0.07 |
| Q2 2023 | $6.2M | -$5.0M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Stereotaxis, Inc. Dividends, Buybacks & Capital Allocation
STXS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Stereotaxis, Inc. (CIK: 0001289340)
📋 Recent SEC Filings
❓ Frequently Asked Questions about STXS
What is the AI rating for STXS?
Stereotaxis, Inc. (STXS) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are STXS's key strengths?
Claude: Exceptional revenue growth of 6833% YoY indicates significant commercial traction in medical device market. Strong gross margin of 52.7% demonstrates viable unit economics and pricing power.
What are the risks of investing in STXS?
Claude: Negative operating cash flow of -$13.7M annually with only $13.4M cash reserves creates critical 12-month survival runway. Operating losses of $22.1M on $32.4M revenue (-68.3% margin) indicate severe inability to convert gross profit to operating profit.
What is STXS's revenue and growth?
Stereotaxis, Inc. reported revenue of $32.4M.
Does STXS pay dividends?
Stereotaxis, Inc. does not currently pay dividends.
Where can I find STXS SEC filings?
Official SEC filings for Stereotaxis, Inc. (CIK: 0001289340) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is STXS's EPS?
Stereotaxis, Inc. has a diluted EPS of $-0.25.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is STXS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Stereotaxis, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is STXS stock overvalued or undervalued?
Valuation metrics for STXS: ROE of -160.5% (sector avg: 15%), net margin of -66.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy STXS stock in 2026?
Our dual AI analysis gives Stereotaxis, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is STXS's free cash flow?
Stereotaxis, Inc.'s operating cash flow is $-13.7M, with capital expenditures of $93.0K. FCF margin is -42.6%.
How does STXS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -66.8% (avg: 12%), ROE -160.5% (avg: 15%), current ratio 1.51 (avg: 2).